BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cerecin (Singapore\, formerly Accera\, Nestle Health Science-b
 acked) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Cerecin (Singapore\, formerly Acc
 era\, Nestle Health Science-backed)'s drugs run\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05809908-718@assetmemo.bio
DTSTAMP:20261121T011245Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Tricaprilin: Phase 3 readout est. (NCT05809908)
DESCRIPTION:Tricaprilin\, phase 3\, Alzheimer's Disease.\nStudy: Tricaprili
 n Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study\nEstimated primar
 y completion: January 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tricaprilin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05809908
URL:https://assetmemo.bio/drug/tricaprilin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
